Eleos Health

The NLP engine is the product. There is no services layer or staffing bureau underneath, and the company describes proprietary voice based natural language understanding built by clinical experts and trained on a large corpus of real-world treatment sessions. The behavioral-health-specific training data is the moat rather than a generic model with a healthcare wrapper, which is what separates this from horizontal scribes pointed at therapy.

Consistently framed as augmented intelligence rather than autonomous, and the company publishes the number that makes the claim checkable: providers accept roughly 80 percent of documentation suggestions, which means one in five is edited or rejected. Publishing an acceptance rate is a rare and useful autonomy disclosure, because it quantifies how much human correction the workflow actually requires rather than asserting that a human is in the loop. Compare CodaMetrix, graded down precisely because its human routing threshold is not published.

The approach is named specifically: voice based natural language understanding, session content decomposed into micro-dialogues, and identification of empirically supported interventions directly from the session. Methods appear in peer reviewed publications, which is more checkable than a marketing description. Graded B rather than A because no model card, base model disclosure or error profile by clinical population is published, and the accuracy figures are reported at aggregate level.

The deepest published evidence base of any documentation-adjacent vendor in the index, and one of very few anywhere in it with a randomised trial. A randomised clinical trial at a community based clinic, published in the Journal of Medical Internet Research, compared the platform against treatment as usual for 47 adults in outpatient CBT for depressive or anxiety disorders and reported roughly double attendance and three to four times greater symptom improvement. A separate JMIR study validated a machine learning model predicting assignment of therapy homework, and a real-world accuracy study evaluated performance across more than 2.83 million micro-dialogues. TWO CAVEATS A BUYER SHOULD CARRY: the RCT is small at n=47 and was conducted at a single community clinic, so it is a feasibility and preliminary efficacy study rather than a definitive one, and the headline outcome multiples are quoted in marketing without that qualifier. The evidence is real and unusually good for this category, but the effect sizes are early.

No specific published detail located on PHI retention, de-identification, or whether customer session recordings are used to train models. This axis carries more weight in behavioral health than anywhere else in the index, since the raw input is recorded psychotherapy audio, and the absence of a published position is itself worth pressing on.

No published BAA terms located at the time of review.

No third party security attestation such as SOC 2 Type II or HITRUST was retrieved at the time of review. Given that the product records therapy sessions, buyers should require the actual report.

Not an FDA regulated product by design. The system documents and analyses sessions and surfaces insight to clinicians and supervisors; it does not diagnose or direct treatment, so it falls outside Software as a Medical Device. Same treatment as Mendel. The relevant regulatory surface is payer documentation and audit compliance rather than FDA, and the Compliance product is aimed squarely at that.

No demographic subgroup performance analysis located, and the exposure here is specific rather than generic. Speech recognition and language models are documented to perform unevenly across accent, dialect and speech patterns, and this system listens to psychotherapy sessions with clients who may have thought disorder, medication effects on speech, or intoxication. Multilanguage support across 150 languages is a genuine access feature but is not the same as published performance parity, and auto-translating notes into English introduces a second unexamined error surface.

Structurally different from per-integration competitors and the difference is real. The platform embeds via a lightweight browser extension, making it EHR agnostic rather than dependent on a build per system, which the company frames as enabling rapid implementation without workflow disruption. Third party listings enumerate compatibility across the behavioral health EHR landscape including Carelogic, Credible, InSync, SmartCare, MyAvatar NX, MyEvolv, EchoVantage, PCE, Kipu, Welligent, eHana and Exym. Behavioral health runs on a long tail of specialty EHRs that horizontal scribes typically cannot reach, so agnostic embedding is a genuine moat in this category specifically.

Browser-embedded SaaS spanning in-office, telehealth and field based settings, with the Outreach product built specifically for providers who travel to clients. Broad coverage of where behavioral health actually happens. No data residency or hosting architecture disclosure located.

No pricing published and no pricing basis disclosed; third party listings confirm pricing is available only on request and that the product targets mid-market and enterprise behavioral health organisations. The outcome claims are quantified but the commercial terms are not, which is the inverse of BrainCheck in the same batch.

Genuinely broad within its vertical: behavioral health, substance use disorder treatment, home health and hospice, spanning individual and group therapy, peer support, case management and prescriber workflows, across office, telehealth and field based settings. It also targets distinct user classes rather than only clinicians, including supervisors, organisational leadership and audit and compliance teams, and supports CCBHC certification and SAMHSA grant reporting workflows. That is unusual depth for a single vertical.